Scarica l'app Stockscreener
34.89
1.83%
-0.65
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.54
Aprire:
$35.15
Volume 24 ore:
1.92M
Relative Volume:
1.66
Capitalizzazione di mercato:
$277.66M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-3.0986
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
+7.82%
1M Prestazione:
-5.68%
6M Prestazione:
+3.35%
1 anno Prestazione:
-49.43%
Intervallo 1D:
$33.81
$35.50
Intervallo di 1 settimana:
$30.82
$36.20
Portata 52W:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Confronta TNXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
34.89 | 277.66M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL - GuruFocus
Tonix Pharmaceuticals: Big Risk, Bigger RewardInitiating With A Buy (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharma Presents Data at Rheumatology Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment a - GuruFocus
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data and Analyses of - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Shows Breakthrough Results, FDA Decision Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP St - GuruFocus
Tonix Pharmaceuticals Announces Appointment of Commercial - GlobeNewswire
Tonix Pharmaceuticals Strengthens Board with Appointment of Jim Hunter - citybuzz -
Tonix Pharmaceuticals Announces Appointment of Commercial Indust - GuruFocus
Tonix Pharmaceuticals Appoints James “Jim” Hunter To Board - citybiz
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP Stock News - GuruFocus
Tonix Pharma Appoints James Hunter to Board - TipRanks
Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion? (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors | TNXP Stock News - GuruFocus
Tonix Strengthens Board with 40-Year Pharma Veteran as FDA Decision on Fibromyalgia Drug Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Files for $500M Mixed Securities Sh - GuruFocus
Tonix Pharmaceuticals stock falls after announcing $225 million share offerings By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals stock falls after announcing $225 million share offerings - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Drops After $500M Shelf Filing - GuruFocus
Tonix Pharmaceuticals (TNXP) Files To Raise $500 Million, Shares Tumble - Benzinga
Tonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not Pessimistic By Stocktwits - Investing.com India
Oxford Industries, GameStop, Boeing And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (TNXP) Files for $500M Mixed Securities Shelf | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Plans Potential Share Sale of Up to $150 Million; Stock Falls Premarket - MarketScreener
Tonix Pharma Signs Major Sales Agreements for Funding - TipRanks
Tonix Pharmaceuticals Holding May Sell Up To $150 Million In Common Stock - marketscreener.com
Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention - citybuzz -
(TNXP) Long Term Investment Analysis - news.stocktradersdaily.com
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO Int - GuruFocus
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention - The Manila Times
Tonix Fibromyalgia Drug Faces Critical FDA Decision: CEO to Present Latest Data at BIO 2025 - Stock Titan
Analysis of Tonix Pharmaceuticals (TNXP) Stock: Performance, News for June 2025 - Investing.com India
Tonix Pharmaceuticals doses first patient in Phase 2 OASIS trial for acute stress reaction - Proactive Investors
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Announces Poster Presentation at the Annua - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the - GlobeNewswire
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 - The Manila Times
Tonix New Fibromyalgia Drug Shows Dual Sleep and Pain Benefits at EULAR 2025 | TNXP Stock News - Stock Titan
Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Defense World
Tonix Pharmaceuticals (TNXP) Price Target Raised to $65 by Alliance Global Partners | TNXP Stock News - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World
Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - Revista ADVFN
How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com
Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):